Overview

A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Anakinra (an interleukin-1 receptor antagonist) can improve hearing thresholds in those patients with Autoimmune Inner Ear Disease (AIED) that did not respond to oral steroid therapy for a sudden decline in hearing. The patients to be enrolled will have recently completed a course of oral steroids and demonstrated no change in their audiometric thresholds following corticosteroid therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Andrea Vambutas
Collaborator:
National Institute on Deafness and Other Communication Disorders (NIDCD)
Treatments:
Interleukin 1 Receptor Antagonist Protein